

Supplementary Appendix

Table of Contents

Supplemental Table 1: Baseline characteristics of patients with data available on prior therapy lines.....	2
Supplemental Table 2: Univariate outcomes of patients based on prior therapy lines	3
Supplemental Table 3: Impact of lines of prior to allogeneic transplant on outcomes (multivariate analysis)	4
Supplemental Table 4: Cause of Death.....	5
Supplemental Figure 1: Hematopoietic recovery.....	6

Supplemental Table 1: Baseline characteristics of patients with data available on prior therapy lines

		1 Prior therapy line	2 Prior therapy lines	3 and more Prior therapy lines	Test p-value
Number of patients		196	250	319	
Age	median (range)[IQR]	54.2 (18.2-71.9) [44.9-59.8]	51.5 (18.2-75.6) [41.1-59]	51.4 (19-71.9) [42-59]	0.18
Gender	Female	59 (30.1)	82 (32.8)	107 (33.5)	0.71
	Male	137 (69.9)	168 (67.2)	212 (66.5)	
KPS	<90	49 (26.2)	72 (30.3)	108 (34.8)	0.12
	>=90	138 (73.8)	166 (69.7)	202 (65.2)	
	missing	9	12	9	
Cell source	Bone marrow	20 (10.2)	24 (9.6)	41 (12.9)	0.42
	Peripheral blood	176 (89.8)	226 (90.4)	278 (87.1)	
Conditioning intensity	Myeloablative	52 (26.7)	82 (33.3)	129 (40.8)	0.004
	RIC	143 (73.3)	164 (66.7)	187 (59.2)	
	missing	1	4	3	
Disease status	CR	129 (67.9)	145 (58.7)	159 (52.3)	0.004
	PR	43 (22.6)	71 (28.7)	87 (28.6)	
	Resistant/Untreated	18 (9.5)	31 (12.6)	58 (19.1)	
	missing	6	3	15	
Comorbidity score	0	72 (50.3)	89 (52)	123 (53.7)	0.34
	[1-2]	38 (26.6)	34 (19.9)	41 (17.9)	
	>2	33 (23.1)	48 (28.1)	65 (28.4)	
	missing	53	79	90	
Histology	AITL	70 (35.7)	76 (30.4)	96 (30.1)	0.06
	ALCL	37 (18.9)	53 (21.2)	92 (28.8)	
	PTCL	89 (45.4)	121 (48.4)	131 (41.1)	
Survival Status	Alive	147 (75)	170 (68)	199 (62.4)	0.01
	Dead	49 (25)	80 (32)	120 (37.6)	

Abbreviations: AITL=angioimmunoblastic T-cell lymphoma, ALCL=anaplastic large cell lymphoma, Haplo=haploidentical, IQR= interquartile range, KPS=Karnofsky performance score, PTCL=peripheral T-cell lymphoma.

Supplemental Table 2: Univariate outcomes of patients based on prior therapy lines

		Overall Survival	Progression-free Survival	Relapse/Progression	Non relapse mortality
At 1 year	1 Line	79.3%[72.6-84.5]	65.2%[57.8-71.6]	22.3%[16.5-28.5]	12.5%[8.2-17.8]
	2 Lines	76.1%[70-81.1]	68%[61.6-73.5]	15.5%[11.2-20.4]	16.6%[12.1-21.6]
	3+ Lines	70.2%[64.7-75]	58.8%[53-64.2]	24%[19.3-28.9]	17.2%[13.2-21.7]
	P value	0.01	0.009	0.1	0.08
At 3 years	1 Line	73.3%[65.6-79.6]	58.9%[50.9-66]	26.9%[20.4-33.7]	14.3%[9.5-20]
	2 Lines	64.2%[56.5-70.9]	52.9%[45.1-60]	23.8%[17.9-30.3]	23.3%[17.4-29.6]
	3+ Lines	59%[52.5-65]	46.4%[40-52.5]	30.7%[25.3-36.2]	22.9%[17.8-28.4]
	P value	0.01	0.01	0.1	0.08

Supplemental Table 3: Impact of lines of prior to allogeneic transplant on outcomes (multivariate analysis)

	Reference group	Overall Survival		Progression-free Survival		Relapse/progression		Non-relapse mortality	
		Hazard ratio (95%CI)	p.value	Hazard ratio (95%CI)	p.value	Hazard ratio (95%CI)	p.value	Hazard ratio (95%CI)	p.value
Number of pre alloHCT lines of therapy									
2 line	1 line	1.4 (1.0-2.1)	0.07	1.1 (0.8-1.5)	0.49	0.8 (0.5-1.2)	0.30	1.8 (1.1-3.0)	0.02
3 and more		1.6 (1.1-2.2)	0.02	1.3 (1.0-1.8)	0.06	1.1 (0.8-1.6)	0.59	1.8 (1.1-2.9)	0.02
		Analysis adjusted for donor source, remission status, patient age, gender and KPS ¹		Analysis adjusted for remission status, patient age, gender and history of prior autologous HCT ¹		Analysis adjusted for remission status, history of prior autologous HCT, KPS and lymphoma histology ¹		Analysis adjusted for donor source, patient age and gender ¹	
¹ These indicate covariates that were independently predictive of overall survival, progression-free survival, relapse/progression and non-relapse mortality.									

Supplemental Table 4: Cause of Death

	Total	Haploidentical donor	HLA identical sibling	MUD TCD+	MUD TCD-
No. of deaths	739	87	344	185	123
Primary disease	238 (34)	32 (38)	115 (36)	54 (30)	37 (31)
Organ failure	77 (11)	16 (19)	30 (9)	17 (10)	14 (12)
Infection(s)	135 (19)	17 (20)	56 (17)	39 (22)	23 (19)
GVHD	113 (16)	7 (8)	46 (14)	34 (19)	26 (22)
Second malignancy	13 (2)	1 (1)	6 (2)	6 (3)	0 (0)
ARDS	5 (1)	0 (0)	4 (1)	1 (1)	0 (0)
Graft rejection	4 (1)	1 (1)	1 (0)	2 (1)	0 (0)
Hemorrhage	8 (1)	0 (0)	4 (1)	3 (2)	1 (1)
Accidental death	2 (0)	0 (0)	1 (0)	0 (0)	1 (1)
Other transplant related cause(s)	90 (13)	10 (12)	49 (15)	17 (10)	14 (12)
Other	15 (2)	0 (0)	9 (3)	4 (2)	2 (2)
Missing	39	3	23	8	5

Abbreviations: ARDS=Acute respiratory distress syndrome; GVHD=graft-versus-host disease

Supplemental Figure 1: Hematopoietic recovery.

